Overview

Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
To evaluate the tolerability and pharmacokinetics of SGI-110 when administered subcutaneously to Japanese patients with acute myeloid leukemia (AML).
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Azacitidine
Guadecitabine